Modality
Fusion Protein
MOA
GLP-1/GIP
Target
PD-1
Pathway
Proteasome
PTSDPSP
Development Pipeline
Preclinical
~Jun 2021
→ ~Sep 2022
Phase 1
Dec 2022
→ Sep 2030
Phase 1Current
NCT08218801
1,104 pts·PSP
2024-02→2030-09·Recruiting
NCT07752673
2,697 pts·PTSD
2022-12→2030-08·Recruiting
3,801 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-08-144.4y awayPh2 Data· PTSD
2030-09-024.4y awayPh2 Data· PSP
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Recruit…
P1/2
Recruit…
Catalysts
Ph2 Data
2030-08-14 · 4.4y away
PTSD
Ph2 Data
2030-09-02 · 4.4y away
PSP
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08218801 | Phase 1/2 | PSP | Recruiting | 1104 | EASI-75 |
| NCT07752673 | Phase 1/2 | PTSD | Recruiting | 2697 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Motanaritide | Intellia | Approved | PD-1 |